Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Weidemann

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
International Journal of Cardiology|May 26, 2015
The cardiomyopathy in Friedreich's ataxia - New biomarker for staging cardiac involvementFrank Weidemann, Dan Liu, Kai Hu, et al.
JIMD Reports|May 17, 2017
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry RegistryWilliam R Wilcox, Ulla Feldt-Rasmussen, Ana Maria Martins, et al.
Orphanet Journal of Rare Diseases|May 5, 2016
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variantMalte Lenders, Frank Weidemann, Christine Kurschat, et al.
Plos One|March 23, 2013
Impact of regional left ventricular function on outcome for patients with AL amyloidosisDan Liu, Kai Hu, Markus Niemann, et al.
Molecular Genetics and Metabolism|November 11, 2018
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of expertsDominique P Germain, Michael Arad, Alessandro Burlina, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2015
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-UpMalte Lenders, Sima Canaan-Kühl, Johannes Krämer, et al.
Molecular Genetics and Metabolism|March 14, 2018
Fabry disease revisited: Management and treatment recommendations for adult patientsAlberto Ortiz, Dominique P Germain, Robert J Desnick, et al.
Circulation Research|March 6, 2004
Cellular mechanisms of contractile dysfunction in hibernating myocardiumVirginie Bito, Frank R Heinzel, Frank Weidemann, et al.
The American Journal of Cardiology|June 7, 2016
Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry CardiomyopathyFrank Weidemann, Sebastian K G Maier, Stefan Störk, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
International Journal of Cardiology|May 26, 2015
The cardiomyopathy in Friedreich's ataxia - New biomarker for staging cardiac involvementFrank Weidemann, Dan Liu, Kai Hu, et al.
JIMD Reports|May 17, 2017
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry RegistryWilliam R Wilcox, Ulla Feldt-Rasmussen, Ana Maria Martins, et al.
Orphanet Journal of Rare Diseases|May 5, 2016
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variantMalte Lenders, Frank Weidemann, Christine Kurschat, et al.
Plos One|March 23, 2013
Impact of regional left ventricular function on outcome for patients with AL amyloidosisDan Liu, Kai Hu, Markus Niemann, et al.
Molecular Genetics and Metabolism|November 11, 2018
The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of expertsDominique P Germain, Michael Arad, Alessandro Burlina, et al.
Molecular Genetics and Metabolism Reports|November 9, 2020
Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: A Fabry Registry analysis stratified by phenotypeRobert J Hopkin, Ulla Feldt-Rasmussen, Dominique P Germain, et al.
Journal of the American Society of Nephrology : JASN|July 18, 2015
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-UpMalte Lenders, Sima Canaan-Kühl, Johannes Krämer, et al.
Molecular Genetics and Metabolism|March 14, 2018
Fabry disease revisited: Management and treatment recommendations for adult patientsAlberto Ortiz, Dominique P Germain, Robert J Desnick, et al.
Circulation Research|March 6, 2004
Cellular mechanisms of contractile dysfunction in hibernating myocardiumVirginie Bito, Frank R Heinzel, Frank Weidemann, et al.
The American Journal of Cardiology|June 7, 2016
Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry CardiomyopathyFrank Weidemann, Sebastian K G Maier, Stefan Störk, et al.
Pageof 16